Literature DB >> 20613907

In reply: Tumor-associated lymphocytes expanded ex vivo from malignant ascites.

Shin Wha Lee1, Yong-Man Kim.   

Abstract

Entities:  

Year:  2010        PMID： 20613907      PMCID： PMC2895715          DOI： 10.3802/jgo.2010.21.2.133

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN： 2005-0380            Impact factor:   4.401


× No keyword cloud information.
  4 in total

1.  Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.

Authors:  Pierpaolo Correale; Maria Saveria Rotundo; Maria Teresa Del Vecchio; Cinzia Remondo; Cristina Migali; Chiara Ginanneschi; Kwong Y Tsang; Antonella Licchetta; Susanna Mannucci; Lucia Loiacono; Pierfrancesco Tassone; Guido Francini; Pierosandro Tagliaferri
Journal:  J Immunother       Date:  2010-05       Impact factor: 4.456

2.  Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.

Authors:  Katsuhiko Shimizu; Masao Nakata; Yuji Hirami; Takuro Yukawa; Ai Maeda; Kazuo Tanemoto
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

3.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

4.  A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer.

Authors:  Tomoyuki Aruga; Eiji Suzuki; Shigehira Saji; Shin-Ichirou Horiguchi; Kazumi Horiguchi; Susumu Sekine; Dai Kitagawa; Nobuaki Funata; Masakazu Toi; Kenichi Sugihara; Katsumasa Kuroi
Journal:  Oncol Rep       Date:  2009-08       Impact factor: 3.906
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.